Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease

Acute Gouty Arthritis Clinical Trial

Official title:
A Randomized Double-blind Active-controlled Trial of Canakinumab Versus Triamcinolone Acetonide on Reducing the Proportion of Patients With Any New Gouty Arthritis Flare(s) in Patients With Chronic Kidney Disease

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to confirm the efficacy and safety results obtained in a chronic kidney disease (CKD) subgroup of patients participating in Phase III studies in a larger, independent patient population with difficult to treat gouty arthritis and moderate to severe CKD (stage 3 - 4).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01593527
Study type	Interventional
Source	Novartis
Contact
Status	Withdrawn
Phase	Phase 3
Start date	September 2012
Completion date	September 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02545777` - The Clinical Study on Treating Acute Gouty Arthritis Using Both Internal and External Therapy of Tonifying Spleen and Descending Turbid	Phase 2
Completed	`NCT01356602` - Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients	Phase 3
Completed	`NCT00170781` - Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout	Phase 4
Not yet recruiting	`NCT06273813` - Treatment of Topical Ketorolac Gel in Acute Gouty Flare	Phase 1
Completed	`NCT03002974` - A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis	Phase 2
Completed	`NCT01431638` - Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients	Phase 3